| P/E (FY) | — | Sales (TTM) | $13.4M |
| Earnings (TTM) | -$1.5M | ROE | −58.72% |
| Net Margin | −6.95% | ROIC | — |
| Debt / Equity | 1.12 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −5.24% |
| Market Cap | $4.1M | Trading Days | 3126 |
| 52W High | 0.10 |
| 52W Low | 0.02 |
| % Off High | −80.00% |
| YTD | −66.67% | 1Y | −50.00% |
| 3Y | −60.00% | 5Y | −93.55% |
| 10Y | −94.52% | Since incept. (ann.) | −19.96% |
| Ann. Volatility (1Y) | 226.18% | Ann. Volatility (3Y) | 200.86% |
| Sharpe (1Y) | 0.64 | Sharpe (3Y) | 0.78 |
| Max Drawdown (1Y) | −80.00% | Max Drawdown (3Y) | −81.54% |
| Beta (3Y, vs SPY) | 0.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| REVB | REVELATION BIOSCIENCES, INC. | $4.1M | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $4.0M | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $4.0M | — |
| ELAB | PMGC Holdings Inc. | $4.3M | — |
| ENSC | Ensysce Biosciences, Inc. | $3.7M | — |
| INBP | INTEGRATED BIOPHARMA INC | $4.7M | 5.0 |
| ACUT | Accustem Sciences Inc. | $3.5M | — |
| RNAZ | Transcode Therapeutics, Inc. | $4.8M | — |
| ENVB | Enveric Biosciences, Inc. | $4.9M | — |
| DRMA | Dermata Therapeutics, Inc. | $5.0M | — |
| APVO | Aptevo Therapeutics Inc. |
| $5.2M |
| — |
| GOVX | GeoVax Labs, Inc. | $5.4M | — |
